Novavax Aktie

7,24 EUR -0,16 EUR -2,18 %

17:12:46

FSE

8,35 USD -0,23 USD -2,68 %

17:23:07

BTT

Novavax jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.1,23 Mrd. EUR

Div. Rendite0,00%

WKNA2PKMZ

ISINUS6700024010

SymbolNVAX

Novavax Aktien News

Sortieren:Datum Meistgelesen

13:00PR NewswireNovavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

07.10.25PR NewswireNovavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment

30.09.25PR NewswireNovavax Announces Progress on Sanofi Agreement

WerbungNovavax-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

04.09.25PR NewswireNuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

03.09.25PR NewswireNovavax to Participate in the Cantor Global Healthcare Conference

27.08.25PR NewswireNovavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

06.08.25PR NewswireNovavax Reports Second Quarter 2025 Financial Results and Operational Highlights

30.07.25PR NewswireNovavax to Report Second Quarter 2025 Financial Results on August 6, 2025

24.07.25PR NewswireNovavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

11.06.25PR NewswireNovavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

29.05.25PR NewswireNovavax to Participate in Upcoming Investor Conferences

19.05.25PR NewswireU.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

08.05.25PR NewswireNovavax Reports First Quarter 2025 Financial Results and Operational Highlights

07.05.25PR NewswireNovavax to Participate in BofA Securities 2025 Health Care Conference

05.05.25PR NewswireNovavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

01.05.25PR NewswireNovavax to Report First Quarter 2025 Financial Results on May 8, 2025

29.04.25PR NewswireNovavax Appoints Charles Newton to Board of Directors

15.04.25PR NewswireSHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

11.03.25PR NewswireNovavax Announces Changes to Board of Directors

27.02.25PR NewswireNovavax to Participate in Upcoming March Investor Conferences

27.02.25PR NewswireNovavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

20.02.25PR NewswireNovavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025

13.12.24PR NewswireNovavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone

10.12.24PR NewswireNovavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza

04.12.24PR NewswireNovavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million

15.11.24PR NewswireNovavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

13.11.24PR NewswireNovavax to Participate in Jefferies London Healthcare Conference

12.11.24PR NewswireNovavax Reports Third Quarter 2024 Financial Results and Operational Highlights

11.11.24PR NewswireU.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

10.11.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

04.11.24PR NewswireNovavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024

04.11.24PR NewswireÅsa Manelius Named Managing Director of Novavax AB Site

02.11.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

27.10.24PR NewswireNVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm

18.10.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

16.10.24PR NewswireUpdate on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

09.10.24PR NewswireNovavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU

25.09.24PR NewswireNovavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

13.09.24PR NewswireNovavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.

04.09.24PR NewswireNovavax to Participate in Upcoming September Conferences

Novavax News

Novavax News: auf dieser Seite finden Sie alle Novavax News und Nachrichten zur Novavax Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novavax News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novavax News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.